FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 358:1638-1639 April 10, 2008 Number 15 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Davì, G. PubMed Citation

To the Editor: In their review of platelet activation and atherothrombosis, Davì and Patrono (Dec. 13, 2007, issue)¹ state that "the clinical benefit associated with P2Y₁₂ blockade by clopidogrel in patients receiving aspirin is relatively modest and inconsistent." However, combining aspirin and clopidogrel is beneficial in certain subgroups. In one study, after percutaneous coronary intervention, combination therapy for 1 year was associated with a 26.9% relative reduction in the combined risk of death, myocardial infarction, or stroke.² The addition of clopidogrel (300 mg in a loading dose, then 75 mg daily) to aspirin also improved patency rates for the infarct-related . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.